Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Share-based Compensation (2018 - 2025)

Serina Therapeutics' Share-based Compensation history spans 8 years, with the latest figure at $46000.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation changed N/A year-over-year to $46000.0; the TTM value through Sep 2025 reached $2.7 million, changed N/A, while the annual FY2024 figure was $2.6 million, 10280.0% up from the prior year.
  • Share-based Compensation for Q3 2025 was $46000.0 at Serina Therapeutics, up from -$896000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.6 million in Q4 2024 and bottomed at -$896000.0 in Q2 2025.
  • The 5-year median for Share-based Compensation is $178000.0 (2021), against an average of $266117.6.
  • The largest annual shift saw Share-based Compensation skyrocketed 2550.0% in 2024 before it crashed 1590.57% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $263000.0 in 2021, then plummeted by 56.65% to $114000.0 in 2022, then tumbled by 64.91% to $40000.0 in 2023, then soared by 6387.5% to $2.6 million in 2024, then crashed by 98.23% to $46000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Share-based Compensation are $46000.0 (Q3 2025), -$896000.0 (Q2 2025), and $956000.0 (Q1 2025).